609 Stock Overview
A biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ABIONYX Pharma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.28 |
| 52 Week High | €1.28 |
| 52 Week Low | €0.95 |
| Beta | 0.053 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -47.78% |
| 5 Year Change | 340.55% |
| Change since IPO | -55.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 609 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | n/a | -17.2% | 8.2% |
Return vs Industry: Insufficient data to determine how 609 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 609 performed against the German Market.
Price Volatility
| 609 volatility | |
|---|---|
| 609 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 609's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 609's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 61 | Cyrille Tupin | abionyx.com |
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019.
ABIONYX Pharma SA Fundamentals Summary
| 609 fundamental statistics | |
|---|---|
| Market cap | €42.31m |
| Earnings (TTM) | -€3.36m |
| Revenue (TTM) | €4.86m |
8.7x
P/S Ratio-12.6x
P/E RatioIs 609 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 609 income statement (TTM) | |
|---|---|
| Revenue | €4.86m |
| Cost of Revenue | €3.92m |
| Gross Profit | €932.00k |
| Other Expenses | €4.29m |
| Earnings | -€3.36m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.097 |
| Gross Margin | 19.19% |
| Net Profit Margin | -69.15% |
| Debt/Equity Ratio | 14.4% |
How did 609 perform over the long term?
See historical performance and comparison